The efficacy of two doses of the anti-COVID-19 vaccine candidate Soberana 02 with Soberana Plus booster against the symptomatic disease is expected to be known next week, informed Dr. María Eugenia Toledo Romaní, principal investigator of the Phase III clinical trial of that immunogen.